Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 3/20 | 0.45 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.44 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.44 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.44 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.42 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.42 |
| ▸ | POLA1 | P09884 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL860462 | 1.00 | DUT (0.45) | DUTSLC29A1SLC28A1SLC28A2SLC28A3 | |
| SCHEMBL20053425 | 1.00 | DUT (0.45) | DUTSLC29A1SLC28A1SLC28A2SLC28A3 | |
| SCHEMBL18672024 | 0.91 | DUT (0.46) | DUTSLC29A1SLC28A1SLC28A2SLC28A3 | |
| SCHEMBL21063983 | 0.91 | DUT (0.46) | DUTSLC29A1SLC28A1SLC28A2SLC28A3 | |
| SCHEMBL17560698 | 0.89 | DUT (0.54) | DUTSLC29A1SLC28A1SLC28A2SLC28A3 | |
| SCHEMBL21418793 | 0.89 | DUT (0.54) | DUTSLC29A1SLC28A1SLC28A2SLC28A3 | |
| SCHEMBL21755901 | 0.89 | DUT (0.47) | DUTSLC29A1SLC28A1SLC28A2SLC28A3 | |
| SCHEMBL12701381 | 0.86 | DUT (0.45) | DUTSLC29A1SLC28A1SLC28A2SLC28A3 | |
| SCHEMBL18269224 | 0.85 | SLC28A1 (0.49) | SLC29A1SLC28A1SLC28A2SLC28A3P2RY2 | |
| SCHEMBL29414441 | 0.85 | SLC28A1 (0.46) | DUTSLC29A1SLC28A1SLC28A2SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057867-A1 | NUCLEOSIDE PHOSPHORAMIDATES | GILEAD SCIENCES INC (US) | 2025-02-20 | — | — | US | disclosed |
| EP-3321275-B1 | CRYSTALLINE FORM OF SOFOSBUVIR | GILEAD SCIENCES INC (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-3290428-B1 | TABLET COMPRISING CRYSTALLINE (S)-ISOPROPYL 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1 (2H)-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YL)METHOXY)(PHENOXY)PHOSPHORYL)AMINO)PROPANOATE | GILEAD PHARMASSET LLC (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3321275-A1 | CRYSTALLINE FORM OF SOFOSBUVIR | Gilead Pharmasset LLC (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-3290428-A1 | TABLET COMPRISING CRYSTALLINE (S)-ISOPROPYL 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1 (2H)-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YL)METHOXY)(PHENOXY)PHOSPHORYL)AMINO)PROPANOATE | Gilead Pharmasset LLC (US) | 2018-03-07 | — | — | EP | disclosed |
| US-20180044367-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. | 2018-02-15 | — | — | US | disclosed |
| EP-2913337-B1 | PROCESS FOR THE PRODUCTION OF SOFOSBUVIR | GILEAD PHARMASSET LLC (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-2609923-B1 | PROCESS FOR THE CRYSTALLISATION OF (S)-ISOPROPYL 2-(((S)-(PERFLUOROPHENOXY)(PHENOXY)PHOSPHORYL)AMINO)PROPANOATE | GILEAD PHARMASSET LLC (US) | 2017-05-24 | — | — | EP | disclosed |
| US-9637512-B2 | Nucleoside phosphoramidates | GILEAD PHARMASSET LLC (US) | 2017-05-02 | — | — | US | disclosed |
| US-20160354400-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. | 2016-12-08 | — | — | US | disclosed |
| EP-2610264-A2 | N-[(2'r)-2'-deoxy-2'-fluoro-2'-methyl-p-phenyl-5'-uridylyl]-l-alanine 1-methylethyl ester and process for its production | Gilead Pharmasset LLC (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20130165644-A1 | NUCLEOSIDE PHOSPHORAMIDATES | GILEAD PHARMASSET LLC (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165401-A1 | NUCLEOSIDE PHOSPHORAMIDATES | GILEAD PHARMASSET LLC (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130137654-A1 | NUCLEOSIDE PHOSPHORAMIDATES | GILEAD PHARMASSET LLC (US) | 2013-05-30 | — | — | US | disclosed |
| EP-2552930-A2 | NUCLEOSIDE PHOSPHORAMIDATES | Gilead Pharmasset LLC (US) | 2013-02-06 | — | — | EP | disclosed |
| EP-2432792-A1 | N- [ (2 ' R) -2 ' -DEOXY-2 ' -FLUORO-2 ' -METHYL-P-PHENYL-5 ' -URIDYLYL]-L-ALANINE 1-METHYLETHYL ESTER AND PROCESS FOR ITS PRODUCTION | Pharmasset, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20110251152-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011123645-A2 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| WO-2010135569-A1 | N- [ (2 ' R) -2 ' -DEOXY-2 ' -FLUORO-2 ' -METHYL-P-PHENYL-5 ' -URIDYLYL] -L-ALANINE 1-METHYLETHYL ESTER AND PROCESS FOR ITS PRODUCTION | PHARMASSET, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20100298257-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165644-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | DUT 10/4885SLC29A1 40/4885SLC28A1 67/4885 |
| US-20250057867-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | DUT 13/4885SLC29A1 36/4885SLC28A1 59/4885 |
| US-20130137654-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | DUT 10/4885SLC29A1 40/4885SLC28A1 67/4885 |
| US-20100298257-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | DUT 10/4885SLC29A1 40/4885SLC28A1 67/4885 |
| US-20130165401-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | DUT 10/4885SLC29A1 40/4885SLC28A1 67/4885 |
| US-20160354400-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | DUT 13/4885SLC29A1 36/4885SLC28A1 59/4885 |
| US-20110251152-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | DUT 13/4885SLC29A1 36/4885SLC28A1 59/4885 |
| US-20180044367-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | DUT 10/4885SLC29A1 40/4885SLC28A1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.